Yeda R&D Company
http://www.yedarnd.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Yeda R&D Company
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Foresite Closes $900m Fund VI As Financial Condition Rebound Begins
Foresite Capital already has invested in multiple high-profile therapeutics firms with its sixth fund, including private Xaira, newly public CG Oncology, and Alumis, which is on the verge of an IPO.
'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o
Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.
'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o
Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- Yeda Research and Development Company
- Weizmann Institute of Science
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice